Efficacy studies of pneumococcal conjugate vaccines
| Country | Vaccine | Schedule | Study design | Primary end point | Status |
| US (northern California) | 7vCRM (Wyeth) | 2/4/6 and 12–15 months | Double blind, randomised, controlled (MenC) | Culture confirmed invasive disease | Completed (Black et al, 200034) |
| Finland | 7vCRM (Wyeth) | 2/4/6 and 12 months | Double blind, randomised, controlled (HepB) | Culture confirmed otitis media | Completed |
| Finland | 7vOMPm (Merck) | 2/4/6 months and 7vOMPm or 23vPS at 12 months | Double blind, randomised, controlled (HepB) | Culture confirmed otitis media | Completed |
| US (Navajo and Apache Indians) | 7vCRM (Wyeth) | 2/4/6 and 12–15 months | Double blind, randomised, controlled (MenC) | Culture confirmed invasive disease | In progress |
| South Africa | 9vCRM (Wyeth) | 6/10/14 weeks | Double blind, randomised, controlled (placebo) | Culture confirmed invasive disease and severe pneumonia | In progress |
Men C, group C meningococcal conjugate vaccine containing CRM197 protein carrier; Hep B, hepatitis B vaccine.